WHO ICTRP trial
Individualized radiotherapy plus PARP inhibitors in locally advanced esophageal…
ChiCTR2400086484 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2400086484 |
|---|---|
| Public title | Individualized radiotherapy plus PARP inhibitors in locally advanced esophageal cancer |
| Scientific title | Individualized radiotherapy plus PARP inhibitors in locally advanced esophageal cancer |
| Primary sponsor | Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | Esophageal Neoplasms |
| Interventions | Treatment Group:Radiotherapy: 50.4 Gy in 28 fractions, from Monday to Friday in weeks 1 to 5, and from Monday to Wednesday in week 6, for a total of 6 weeks. Pamiparib 40mg orally twice a day, from Monday to Friday in weeks 1 to 5, and from… |
| Registration date | Jul 2, 2024 |
| Target size | Treatment Group:55 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: